Kaposi's sarcoma in the early post-transplant period in a kidney transplant recipient.
Zafer
Z
Ercan
Mehmet E
ME
Demir
Ozgur
O
Merhametsiz
Ozlem
O
Yayar
Turgay
T
Ulas
Mehmet D
MD
Ayli
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D057210:Delayed Diagnosis; D003872:Dermatitis / Q000175:diagnosis; D003951:Diagnostic Errors; D057915:Drug Substitution; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016030:Kidney Transplantation; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000627:therapeutic use; D011183:Postoperative Complications / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D011184:Postoperative Period; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D020123:Sirolimus / Q000009:adverse effects / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use; D014747:Vinblastine / Q000008:administration & dosage
D007166:Immunosuppressive Agents; D001761:Bleomycin; D014747:Vinblastine; D009173:Mycophenolic Acid; D011241:Prednisone; D020123:Sirolimus; D016559:Tacrolimus